Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
出版年份 2011 全文链接
标题
Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
作者
关键词
-
出版物
CIRCULATION
Volume 124, Issue 21, Pages 2338-2349
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2011-10-18
DOI
10.1161/circulationaha.111.041418
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Activation of the A3 adenosine receptor inhibits fMLP-induced Rac activation in mouse bone marrow neutrophils
- (2010) Dharini van der Hoeven et al. BIOCHEMICAL PHARMACOLOGY
- Reduced airway inflammation in CD26/DPP4-deficient F344 rats is associated with altered recruitment patterns of regulatory T cells and expression of pulmonary surfactant proteins
- (2010) A. Schmiedl et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Sitagliptin (MK0431) Inhibition of Dipeptidyl Peptidase IV Decreases Nonobese Diabetic Mouse CD4+ T-Cell Migration Through Incretin-Dependent and -Independent Pathways
- (2010) S.-J. Kim et al. DIABETES
- Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
- (2010) M. Sauve et al. DIABETES
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2010) Joshua J Neumiller et al. PHARMACOTHERAPY
- Autocrine Purinergic Receptor Signaling Is Essential for Macrophage Chemotaxis
- (2010) M. Kronlage et al. Science Signaling
- Tumor Necrosis Factor-α Potentiates RhoA-Mediated Monocyte Transmigratory Activity In Vivo at a Picomolar Level
- (2009) Sunny Lim et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
- (2009) David J Grieve et al. BRITISH JOURNAL OF PHARMACOLOGY
- Ambient Air Pollution Exaggerates Adipose Inflammation and Insulin Resistance in a Mouse Model of Diet-Induced Obesity
- (2009) Qinghua Sun et al. CIRCULATION
- Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions
- (2009) Siegfried Ansorge et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice
- (2009) Dirk Reinhold et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
- (2009) Hongbin Liu et al. JOURNAL OF ENDOCRINOLOGY
- Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies
- (2009) Kiwon Ban et al. Journal of the American Society of Hypertension
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Incretin-based therapies for type 2 diabetes mellitus
- (2009) Julie A. Lovshin et al. Nature Reviews Endocrinology
- Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites
- (2009) F. K. Swirski et al. SCIENCE
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
- (2009) Roger Yazbeck et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP
- (2008) Brian D. Green et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
- (2008) R CHRISTOPHER et al. CLINICAL THERAPEUTICS
- Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
- (2008) P COVINGTON et al. CLINICAL THERAPEUTICS
- Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice
- (2008) Yusuke Moritoh et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Stromal cell-derived factors 1α and 1β, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8
- (2008) Katerina Ajami et al. FEBS LETTERS
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
- DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis
- (2007) Dirk Reinhold Frontiers in Bioscience-Landmark
- DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
- (2007) Carolyn et al. Frontiers in Bioscience-Landmark
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started